PEPCID PRESERVATIVE FREE Drug Patent Profile

Which patents cover Pepcid Preservative Free, and what generic alternatives are available?

Pepcid Preservative Free is a drug marketed by Merck and Merck Sharp Dohme and is included in two NDAs.

The generic ingredient in PEPCID PRESERVATIVE FREE is famotidine. There are eighteen drug master file entries for this compound. One hundred and thirty-nine suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pepcid Preservative Free

A generic version of PEPCID PRESERVATIVE FREE was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Summary for PEPCID PRESERVATIVE FREE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for PEPCID PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PEPCID PRESERVATIVE FREE	famotidine	INJECTABLE;INJECTION	019510-004	Nov 4, 1986		DISCN	Yes	No
Merck Sharp Dohme	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER	famotidine	INJECTABLE;INJECTION	020249-001	Feb 18, 1994		DISCN	Yes	No

International Patents for PEPCID PRESERVATIVE FREE

See the table below for patents covering PEPCID PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
France	2462431	NOUVEAU COMPOSE DU GUANIDINOTHIAZOLE, SON PROCEDE DE PREPARATION ET DES COMPOSITIONS MEDICALES CONTENANT DE TELS COMPOSES
United Kingdom	2055800	GUANIDINOTHIAZOLES AND THEIR PREPARATION AND USE
Netherlands	8001361

Investment Scenario and Fundamentals Analysis of PEPCID PRESERVATIVE FREE

Last updated: February 20, 2026

What is the current market positioning of PEPCID PRESERVATIVE FREE?

PEPCID PRESERVATIVE FREE is a formulation of famotidine, a histamine-2 blocker used to treat gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. As a preservative-free formulation, it targets patients with sensitivities to preservatives, expanding its market appeal.

In the US, famotidine's original formulations, including PEPCID, have faced patent expiration. However, preservative-free variants have sustained interest due to safety concerns linked to preservatives like benzalkonium chloride. The drug is marketed primarily through prescription channels, with limited over-the-counter (OTC) sales.

How does the regulatory environment impact the investment outlook?

Famotidine patents expired in 2019, leading to increased generic competition. The preservative-free formulation obtained FDA approval in 2018, ensuring market exclusivity for a limited period before generic versions emerged.

The FDA's stance on preservative safety influences market dynamics. Concerns over preservative-related adverse effects have led to heightened demand for preservative-free formulations, potentially providing a competitive edge against traditional generics.

What are the key supply chain and manufacturing considerations?

Manufacturers of PEPCID PRESERVATIVE FREE must ensure adherence to Good Manufacturing Practices (GMP) to maintain drug quality. The formulation's stability depends on sterile processing and packaging. As market competition intensifies, production costs and scale become critical for maintaining margins.

Supply chain risks include sourcing pharmaceutical-grade famotidine and consumables for sterile, preservative-free packaging. Regulatory audits may lead to production delays, impacting availability.

What is the competitive landscape?

The US market features multiple generic famotidine products, including OTC and prescription versions. For the preservative-free segment:

• Main competitors include other prescription famotidine formulations.
• Limited branded preservative-free options exist, offering potential differentiation.

The entry of new generics post-patent expiry has compressed margins, but niche formulations, such as preservative-free variants, retain some premium owing to safety perceptions.

How does patent lifecycle and exclusivity influence investment timing?

PEPCID PRESERVATIVE FREE's initial FDA approval garnered a period of market exclusivity, which has since expired with the advent of generics. Immediate investment viability depends on:

• Continued market acceptance driven by safety concerns.
• Regulatory exclusivities, such as pediatric or Orphan Drug status (though no current indication suggests this).
• Patent rights related to manufacturing processes or delivery mechanisms that could extend exclusivity.

Financial performance and sales trends

Prescription sales of PEPCID (including preservative-free and traditional) declined significantly after patent expiry, with US sales falling from peak levels of approximately $350 million (2018) to less than $100 million in recent years, according to IQVIA data.

While prescriber preferences lean toward newer PPIs (e.g., omeprazole), preservative-free formulations may maintain niche sales amongst sensitive patient groups, possibly stabilizing revenue streams.

Market entry and expansion prospects

Opportunity exists in:

• Expanded OTC availability targeting consumers with preservative sensitivity.
• International markets with high prevalence of GERD and stronger demand for preservative-free medications.
• Developing formulations for pediatric or specialized populations.

Regulatory approval processes in international jurisdictions vary, impacting timelines and investment risk.

Key risks

• High generic competition erodes margins.
• Price erosion due to increased availability of OTC and generic alternatives.
• Regulatory changes impacting formulary access or manufacturing standards.
• Limited patent protections for preservative-free formulations.

Key Opportunities

• Growth in niche markets targeting patients with preservative sensitivities.
• Potential partnership with pharmacy chains for OTC distribution.
• Continued emphasis on safety profile for preservative-free drugs in marketing.

Key Takeaways

• PEPCID PRESERVATIVE FREE initially benefited from formulation-specific exclusivity but now faces intense generic competition.
• Its market value depends heavily on safety perceptions and niche demand driven by patient sensitivities.
• The competitive landscape is characterized by declining prescription sales but potential in OTC and international markets.
• Regulatory, manufacturing, and patent challenges constrain near-term expansion.
• Strategic investments should focus on niche differentiation and market expansion potential.

FAQs

1. What is the patent status of PEPCID PRESERVATIVE FREE?
The original patent expired in 2019, leading to generic entry. No additional patents confer exclusive rights currently.

2. Can PEPCID PRESERVATIVE FREE be marketed OTC?
Limited OTC options exist; expanding OTC availability depends on regulatory approvals and strategic decisions by manufacturers.

3. How significant is the safety benefit of preservative-free formulations?
Clinical evidence links preservatives like benzalkonium chloride to adverse effects, especially in sensitive populations. This consumer perception sustains demand.

4. Is there international demand for preservative-free famotidine?
Yes, countries with high GERD prevalence and regulatory emphasis on safety features show interest. Market entry depends on local approval processes.

5. What are the primary factors to consider before investing?
Market saturation from generics, regulatory risks, manufacturing costs, and the ability to differentiate via safety profile.

---

References

1. IQVIA. (2022). Prescription drug sales data.
2. U.S. Food and Drug Administration. (2018). Approval of preservative-free famotidine.
3. FDA. (2020). Guidance on preservative safety and regulations.
4. MarketWatch. (2022). Over-the-counter and prescription famotidine sales analysis.
5. European Medicines Agency. (2021). International regulations for gastrointestinal drugs.

[1] IQVIA. (2022). Prescription Drug Sales Data.
[2] FDA. (2018). Labeling and approval documentation for preservative-free famotidine.
[3] U.S. Food and Drug Administration. (2020). Guidance on preservative safety.
[4] MarketWatch. (2022). Market trends in famotidine sales.
[5] European Medicines Agency. (2021). Medical product regulations.